Romualdo Barroso: ddAC vs q3wAC regimen in pts with TNBC treated with pembrolizumab plus CT in the neoadjuvant setting

Romualdo Barroso, Medical Oncologist, Head of Research in Oncology and National Leader of Breast Cancer at Dasa shared a post on X:

• “We are pleased with the publication of the Neo-Real study (GBECAM-0123), which evaluated RWD from 10 Brazilian centers, comparing ddAC vs q3wAC regimen in pts with TNBC treated with pembrolizumab plus CT in the neoadjuvant setting.
  
• A pCR was observed in 65.4% with ddAC and 58.7% with q3w AC (P = 0.260), while RCB 0-1 occurred in 82.4% and 73.5%, respectively (P = 0.115). Pts with stage III had a higher pCR with ddAC (59% vs 40%, P = 0.155), while pCR rates were similar regardless of AC regimen in stage II.
• 
• While no significant disparities in drug discontinuation was noted, ddAC showed a trend towards higher rates of grade ≥3 AE (40.5% vs. 30.7%, P = 0.092). We hope to present survival outcomes in the future.”

Dose-dense neoadjuvant chemotherapy in triple-negative breast cancer: Real-world data from a developing country

Authors: Rakesh Kumar Sharma, Ajay Gogia, Svs Deo, Dayanand Sharma, Sandeep Mathur, and Hari Krishna Raju Sagiraju

Source: Romualdo Barroso/X